Clinical trial
Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.
NCT00525707 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2003
- Completion date
- January 31, 2005
- Enrollment
- 735 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.
acute decompensation of chronic heart failure, acute heart failure, new onset of heart failure